ApexOnco Front Page Recent articles 14 March 2025 Sutro calls time on folate At long last luvelta-T is shelved, and Sutro seeks a new focus. 13 March 2025 Ono takes on Takeda in polycythemia vera The Japanese group licenses sapablursen from Ionis for $280m. 1 November 2024 Essa terminates an N-terminal journey After beating "historical" Xtandi masofaniten fails to beat actual Xtandi. 1 November 2024 FDA red and green lights: October 2024 October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed. 31 October 2024 No SOS for Bayer's SOS1 The group goes after a KRAS-related target on which Boehringer recently gave up. 31 October 2024 The month ahead: November’s upcoming events Conferences ramp up, and ASH abstracts near. 29 October 2024 Clouds loom for Novartis’s MorphoSys buy Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase. 28 October 2024 Triple meeting 2024 – Revolution shows selective KRAS promise RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer. Load More Recent Quick take Pivotal Merck/Kelun TROP2 studies seek nearly 10,000 patients 21 May 2024 A second dato-dxd/Tagrisso combo 17 May 2024 US knocks back another Chinese PD-1 entrant 17 May 2024 ESMO Breast Cancer 2024 – Arvinas rises as vepdegestrant stays the same 16 May 2024 Astra holds its own in stage III lung cancer 13 May 2024 Gilead and Arcellx Immagine the future 10 May 2024 iTeos’s TIGIT enters Arcus territory 10 May 2024 Keynote-B21 checks Keytruda’s endometrial advance 9 May 2024 2seventy bets the house on an Abecma renaissance 9 May 2024 Another Zynlonta shift? 8 May 2024 Load More Most Popular